Developing a portfolio of precision therapeutics deploying multi-faceted cancer inhibition strategies
Publications and Posters
AUM001
AUM601
AUM302
AUM003
AUM001
Publications:
- The structure and kinetics of the novel selective inhibitor ETC-206 used against Blast Crisis Chronic Myeloid Leukemia
- The role of eIF4E in the tumour progression of blast crisis chronic myeloid leukemia
- Novel Mnk Inhibitors activities and interactions modelled using computational approaches
- The interactions between inhibitors and Mnk kinases determining a key role in their stability and potency
AUM601
Publications:
AUM302
Publications :
- Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. (2021)
- Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer (2020)
- Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma (2020)
- Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.(2020)
- Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models (2018)
- Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC (2017)
- Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma (2016)
- Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL) (2015)
- Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma (2014)
- Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors (2013)
AUM003